AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh (ABBV34) Price & Analysis

ABBV34 Stock Chart & Stats

R$101.50-R$0.30(-0.29%)

At close: Oct 30 4:00 PM EDT

Day’s Range: BRL 97.00 - BRL 101.50
52-Week Range: BRL 58.81 - BRL 101.80
Previous Close: BRL 101.80
Volume: N/A
Average Volume (3M): 1,079
Market Cap: BRL 2.83T
Enterprise Value: BRL 476.39B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): 5546.4
Beta: -0.49
Next Earnings: Feb 03, 2027
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: 1.48%

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh News

AbbVie: Solid Q3 Execution and Modest EPS Upside Prompt Hold Rating, Price Target Maintained at $294

Analyst Asad Haider from Goldman Sachs maintained a Hold rating on AbbVie and keeping the price target at $294.00. Asad Haider has given his Hold rating due to a combination

1d agoABBV 4AB

Midday Fly By: Amazon and Intel slide, Binance suffers massive hack

The major averages were sharply lower, with the Nasdaq down over 600 points, as downbeat outlooks from tech giants Amazon and Intel extend a wider sector selloff amid investor concerns

2d agoD Z

AbbVie Science Chief says interested in building out obesity assets

AbbVie (ABBV) Chief Scientific Officer Roopal Thakkar said on the company’s earnings call: “Yes, we continue to have interest to build out obesity assets. We are open to anything that

2d agoLLY NVO

AbbVie says too early to determine financial impact from 340B rebate pilot

10:00 EDT AbbVie (ABBV) says too early to determine financial impact from 340B rebate pilot Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

2d agoABBV 4AB

AbbVie sees Q4 adjusted EPS $3.83-$3.87, consensus $3.89

Sees Q4 revenue about $18.4B, consensus $18.3B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts

2d agoABBV 4AB

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

09:35 EDT AbbVie (ABBV) sees FY26 adjusted gross margin ‘above 84% of sales’ Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

2d agoABBV 4AB

AbbVie sees FY26 Skyrizi revenue $21.8B, FY26 Rinvoq revenue $10.3B

09:40 EDT AbbVie (ABBV) sees FY26 Skyrizi revenue $21.8B, FY26 Rinvoq revenue $10.3B Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

2d agoABBV 4AB

AbbVie says making ‘significant progress’ advancing pipeline

Says delivering “strong execution” across the business. Says Skyrizi, Rinvoq “exceeding expectations.” Comments taken from Q3 earnings conference call. Published first on TheFly – the ultimate source for real-time, market-moving

2d agoABBV 4AB

AbbVie sees FY26 revenue about $67.8B, consensus $67.62B

Prior view was FY26 revenue about $67.6B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts

2d agoABBV 4AB

Morning Movers: Intel continues to plummet after earnings

Stock futures are sharply lower as disappointing outlooks from Amazon and Intel extend a technology-sector selloff. Amazon’s holiday-quarter sales outlook disappointed, while Intel also issued a weaker-than-expected Q4 forecast. Alphabet

2d agoGD AZN

AbbVie reports Q3 adjusted EPS $3.82, consensus $3.77

Reports Q3 revenue $17.4B, consensus $17.34B. “AbbVie (ABBV) continues to deliver outstanding results, reflecting solid execution across our diverse portfolio,” said Robert Michael, chairman and chief executive officer, AbbVie. “We

2d agoABBV 4AB

AbbVie Buy Rating Reaffirmed as Lutikizumab De-Risks HS Outlook; $310 Price Target Maintained

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie, with a price target of $310.00. Terence Flynn has given his Buy rating due

1w agoABBV 4AB

AbbVie: Hold Rating Maintained as Incremental Lutikizumab Data Support Neutral Stance; Price Target Reaffirmed at $275

AbbVie, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Yee from UBS maintained a Hold rating on the stock and has a $275.00 price

1w agoABBV 4AB

Analyst Reaffirms Buy Rating on AbbVie, Maintaining $280 Price Target After Strong CERVINO Phase III Data

Analyst Steve Scala of TD Cowen maintained a Buy rating on AbbVie, retaining the price target of $280.00. Steve Scala’s rating is based on the view that etentamig’s Phase III

1M agoABBV 4AB

ABBV34 FAQ

What was AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s price range in the past 12 months?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh lowest stock price was R$58.81 and its highest was R$101.80 in the past 12 months.

What is AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s market cap?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s market cap is R$2.83T.

When is AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s earnings last quarter?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh released its earnings results on Oct 30, 2026. The company reported R$0.012 earnings per share for the quarter.

Is AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh pay dividends?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh does not currently pay dividends.

What is AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s EPS estimate?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh have?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh has 1,767,117,300 shares outstanding.

What happened to AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh’s price movement after its last earnings report?

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh reported an EPS of R$0.012 in its last earnings report. Following the earnings report the stock price went down -0.295%.

Which hedge fund is a major shareholder of AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh?

Currently, no hedge funds are holding shares in BR:ABBV34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh (ABBV34) Earnings & Revenues

Historic Earnings Reports

ABBV34 Net sales Breakdown

49.72% Immunology
10.83% Oncology
7.95% Aesthetics
17.60% Neuroscience
3.45% Eye Care
10.40% Other Key Products

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	1	6
Technical Analysis	3	1	6
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to BR:ABBV34
Company	Price & Change	Follow
BR:AMGN34Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh
BR:BMYB34Bristol-Myers Squibb Company Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh
BR:JNJB34Johnson & Johnson Shs Unsponsored Brazilian Depository Receipt Repr 0.0666667 Sh
BR:MRCK34Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh
BR:PFIZ34Pfizer Inc Shs Unsponsored Brazilian Depository Receipts Repr 0.25 Sh

Compare BR:ABBV34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh stock analysis

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh (ABBV34) Price & Analysis

ABBV34 Stock Chart & Stats

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh News

AbbVie: Solid Q3 Execution and Modest EPS Upside Prompt Hold Rating, Price Target Maintained at $294

Midday Fly By: Amazon and Intel slide, Binance suffers massive hack

AbbVie Science Chief says interested in building out obesity assets

AbbVie says too early to determine financial impact from 340B rebate pilot

AbbVie sees Q4 adjusted EPS $3.83-$3.87, consensus $3.89

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

AbbVie sees FY26 Skyrizi revenue $21.8B, FY26 Rinvoq revenue $10.3B

AbbVie says making ‘significant progress’ advancing pipeline

AbbVie sees FY26 revenue about $67.8B, consensus $67.62B

Morning Movers: Intel continues to plummet after earnings

AbbVie reports Q3 adjusted EPS $3.82, consensus $3.77

AbbVie Buy Rating Reaffirmed as Lutikizumab De-Risks HS Outlook; $310 Price Target Maintained

AbbVie: Hold Rating Maintained as Incremental Lutikizumab Data Support Neutral Stance; Price Target Reaffirmed at $275

Analyst Reaffirms Buy Rating on AbbVie, Maintaining $280 Price Target After Strong CERVINO Phase III Data

ABBV34 FAQ

AbbVie Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh (ABBV34) Earnings & Revenues

ABBV34 Net sales Breakdown

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium